Shares of Evotec AG (NASDAQ:EVO – Get Free Report) have been assigned a consensus recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $3.00.
EVO has been the topic of a number of recent research reports. TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, July 15th. Berenberg Bank downgraded Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a report on Tuesday, July 21st. Wall Street Zen cut shares of Evotec from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright dropped their price objective on shares of Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, July 15th.
View Our Latest Research Report on Evotec
Evotec Stock Up 2.6%
Hedge Funds Weigh In On Evotec
Several institutional investors and hedge funds have recently bought and sold shares of the company. Optiver Holding B.V. grew its stake in shares of Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after buying an additional 242,973 shares during the period. WCM Investment Management LLC raised its position in shares of Evotec by 12.1% during the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after buying an additional 67,917 shares during the period. Apollon Wealth Management LLC acquired a new position in Evotec in the first quarter valued at approximately $28,000. SmartHarvest Portfolios LLC acquired a new position in Evotec in the first quarter valued at approximately $44,000. Finally, XTX Topco Ltd grew its position in Evotec by 25.1% in the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after acquiring an additional 3,709 shares during the period. 5.81% of the stock is currently owned by institutional investors and hedge funds.
Evotec Company Profile
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.
Further Reading
- Five stocks we like better than Evotec
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
